Omeros (OMER) Stock Price, News & Analysis

Company Overview

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway. Omeros conducts research and clinical development primarily from the United States, with clinical programs potentially involving international sites. Gregory A. Demopulos, M.D., is the company’s founder, chairman and chief executive officer.

Key Stats

• Today's Range: $16.11 to $16.78
• 50-Day Range: $13.71 to $21.05
• 52-Week Range: $6.24 to $21.24
• Volume: 725,296 shs
• Average Volume: 1.31 million shs
• Market Capitalization: $1.20 billion
• P/E Ratio: 5.99
• Dividend Yield: N/A
• Price Target: $30.33
• Consensus Rating: Moderate Buy

Omeros Stock Analysis - MarketRank™

Omeros scored higher than 73% of companies evaluated by MarketBeat, and ranked 219th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omeros has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Omeros has a consensus price target of $30.33, representing about 83.3% upside from its current price of $16.55.

Amount of Analyst Coverage

Omeros has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omeros are expected to grow in the coming year, from ($0.37) to $1.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omeros is 5.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omeros is 5.99, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 177.10.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.57% of the float of Omeros has been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 6.95.

Change versus previous month

Short interest in Omeros has recently decreased by 8.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omeros does not currently pay a dividend.

Dividend Growth

Omeros does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.39

News Sentiment

Omeros has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Omeros this week, compared to 5 articles on an average week.

Search Interest

5 people have searched for OMER on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Omeros insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,989,705.00 in company stock.

Percentage Held by Insiders

10.50% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OMER
• CIK: 1285819
• Web: www.omeros.com
• Phone: (206) 676-5000
• Fax: 206-676-5005
• Employees: 175
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Omeros: $30.33
• High Price Target: $36.00
• Low Price Target: $22.00
• Potential Upside/Downside: +83.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.28
• Trailing P/E Ratio: 5.99
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.35 million
• Net Margins: N/A
• Pretax Margin: 308.76%
• Return on Equity: -164.92%
• Return on Assets: 69.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $1.89 per share
• Price / Cash Flow: 8.74
• Book Value: ($1.71) per share
• Price / Book: -9.68

Miscellaneous

• Outstanding Shares: 72,390,000
• Free Float: 64,787,000
• Market Cap: $1.20 billion
• Optionable: Optionable
• Beta: 2.57